John Libbey Eurotext

My cart ( )

Bulletin du Cancer

Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab Volume 99, numéro 2, Février 2012

  • Auteur(s) : Élodie Vauleon, Habiba Mesbah, Daniel Gedouin, Isabelle Lecouillard, Guillaume Louvel, Abderrahmane Hamlat, Laurent Riffaud, Béatrice Carsin, Véronique Quillien, Odile Audrain, Thierry Lesimple , Centre Eugène-Marquis, département d’oncologie médicale, CS 44229, 35042 Rennes Cedex, France, UMR 6061 CNRS, université de Rennes-I, IFR 140, CS34317, 35043 Rennes Cedex, France, Centre Eugène-Marquis, département d’information médicale, avenue Bataille-Flandres-Dunkerque, CS 44229, 35042 Rennes Cedex, France, Centre Eugène-Marquis, département de radiothérapie, CS 44229, 35042 Rennes Cedex, France, CHU Ponchaillou, département de neurochirurgie, 35033 Rennes, France, CHU Ponchaillou, département de radiologie, 35033 Rennes, France, Centre Eugène-Marquis, département de biologie, CS 44229, 35042 Rennes Cedex, France
  • Mots-clés : glioblastoma, recurrence, bevacizumab, irinotecan
  • Page(s) : 121-6
  • DOI : 10.1684/bdc.2011.1528
  • Année de parution : 2012

Despite progress in the initial management of glioblastoma (GB), the vast majority of patients will experience recurrence within 2-3 years. The medical treatment of these recurrences is being modified by the use of antiangiogenic therapies. Twenty-four patients, who relapsed from GB after chemoradiation followed by adjuvant temozolomide in Rennes, were treated by conventional chemotherapy (nitrosourea) or by the combination of irinotecan and bevacizumab. In this retrospective analysis, overall survival from diagnosis of recurrence was significantly longer in patients treated with the combination of bevacizumab and irinotecan than with nitrosourea (5 months versus 11,5 months). The combination of irinotecan and bevacizumab appeared to provide clinical benefit to patients with recurrent GB.

Illustrations

Ouvrir l'onglet